Parkside Financial Bank & Trust Makes New $64,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Parkside Financial Bank & Trust acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,733 shares of the biopharmaceutical company’s stock, valued at approximately $64,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Vontobel Holding Ltd. acquired a new stake in shares of Halozyme Therapeutics in the third quarter worth $249,000. Exchange Traded Concepts LLC boosted its position in shares of Halozyme Therapeutics by 16.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 14,129 shares of the biopharmaceutical company’s stock valued at $540,000 after acquiring an additional 1,974 shares in the last quarter. Handelsbanken Fonder AB increased its stake in Halozyme Therapeutics by 8.2% in the third quarter. Handelsbanken Fonder AB now owns 23,869 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 1,800 shares during the period. Linden Thomas Advisory Services LLC raised its position in Halozyme Therapeutics by 13.7% in the third quarter. Linden Thomas Advisory Services LLC now owns 42,450 shares of the biopharmaceutical company’s stock worth $1,622,000 after purchasing an additional 5,126 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in Halozyme Therapeutics by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock worth $619,000 after purchasing an additional 347 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $6,473,094.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 30,000 shares of company stock valued at $1,196,800 over the last ninety days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Down 1.7 %

Shares of HALO stock opened at $38.46 on Friday. The stock has a 50-day moving average of $39.84 and a 200-day moving average of $37.81. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock has a market cap of $4.89 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 0.45 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1-year low of $29.85 and a 1-year high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of analyst reports. JMP Securities reissued a “market outperform” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. Benchmark reissued a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Finally, The Goldman Sachs Group decreased their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.